<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577199</url>
  </required_header>
  <id_info>
    <org_study_id>1112012095</org_study_id>
    <nct_id>NCT01577199</nct_id>
  </id_info>
  <brief_title>RCT of Low-dose Clomiphene vs. High Dose Gonadotropin Protocol for IVF Poor Responders</brief_title>
  <acronym>CLOVANT</acronym>
  <official_title>Randomized Prospective Controlled Non-inferiority Trial of Low-dose Clomiphene Based Antagonist Protocol vs. High Dose Gonadotropin/Antagonist Protocol for IVF Poor Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is compare two commonly-used medication protocols ( low-dose
      clomiphene citrate and high dose gonadotropin protocols) for the treatment of patients with
      diminished ovarian reserve (decreased number of eggs remaining in the ovary) undergoing IVF.
      This research is being done because we do not know if these two medication protocols are
      equally likely to help a woman become pregnant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this protocol is to prospectively evaluate whether a clomid-based, low dose
      gonadotropin protocol (225 IU) would be non-inferior in terms of mature oocyte yield (eggs
      that are ready to be fertilized) as compared to a high-dose protocol.

      Patients meeting the criteria for poor ovarian response will be consented and randomized to
      either a stimulation protocol involving pretreatment with a 0.1mg estradiol patch in the
      luteal phase starting 10 days after the LH surge (the hormone released by the brain to cause
      ovulation to occur, which is detectable in urine) followed by oral clomiphene citrate 100mg
      on days 2-6 of the menstrual cycle and 225 international units of gonadotropins starting on
      day 5, or to the control group involving the same pretreatment with 0.1mg luteal estradiol
      patches starting 10 days after the LH surge, with high dose gonadotropins (600IU) alone,
      starting on day 2 of the cycle. After randomization, patients will undergo routine IVF
      procedures, monitoring, blood draws, cancellation criteria, oocyte retrieval, and embryo
      transfer as non-study participants.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no subjects recruited
  </why_stopped>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of mature oocytes retrieved</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the number of mature oocytes retrieved in two different IVF protocols for poor responders</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of embryos transferred</measure>
    <time_frame>1year</time_frame>
    <description>To evaluate the number of embryos transferred</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>High dose gonadotropins</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose gonadotropins protocol compared to Low-dose Clomiphene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose Clomiphene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>clomid-based, low dose gonadotropin protocol compared to High dose gonadotropins</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose Clomiphene</intervention_name>
    <description>Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed by clomiphene citrate 100mgon days 2-6 of the menstrual cycle with 225 international units of gonadotropins (eg Follistim , Menopur) starting on day 5</description>
    <arm_group_label>Low-dose Clomiphene</arm_group_label>
    <other_name>clomiphene citrate with low dose gonadotropins</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose gonadotropins</intervention_name>
    <description>Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed high dose gonadotropins (eg. Follistim. Menopur) 600IU starting on day 2 of the cycle</description>
    <arm_group_label>High dose gonadotropins</arm_group_label>
    <other_name>Gonal F or Follistim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients age 18-42 undergoing IVF

          -  AFC &lt;7 (see definition above) and AMH (see definition above) &lt;0.5 and/or prior poor
             IVF response

        Exclusion Criteria:

          -  BMI (body mass index) &gt;30

          -  PGD (preimplantation genetic diagnosis, in which embryos are biopsied to rule out
             chromosomal abnormalities)

          -  Age &gt;42

          -  Fragile X carriers (a condition associated with premature ovarian aging)

          -  TESE (Testicular sperm extraction)

          -  Asherman's syndrome (uterine scarring which can affect implantation and pregnancy)

          -  Untreated hydrosalpinx (accumulated fluid in the fallopian tube which may be toxic to
             embryos)

          -  &gt;6 prior attempted cycles
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Owen Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>WCMC</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.IVF.org</url>
    <description>Center for Reproductive Medicine</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2012</study_first_posted>
  <last_update_submitted>December 15, 2016</last_update_submitted>
  <last_update_submitted_qc>December 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IVF</keyword>
  <keyword>poor responder</keyword>
  <keyword>low ovarian reserve</keyword>
  <keyword>ART</keyword>
  <keyword>ovarian stimulation</keyword>
  <keyword>IVF protocols</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

